The Endothelial Tyrosine Phosphatase SHP-1 Plays an Important Role for Vascular Haemostasis in TNFα-Induced Inflammation In Vivo
Figure 4
Inhibtion SHP-1 does not affect platelet aggregation in vitro and ex vivo. (a) In platelet-rich plasma (PRP) from healthy human volunteers SHP-1 inhibition by sodium stibogluconate did not increase platelet aggregation neither under basal conditions nor after pretreatment with TNFα (5 ng/mL, 4 h) upon stimulation with the platelet agonists ADP, collagen, or thrombin-receptor activating peptide (TRAP) in different concentrations (low ADP: 0.5–1 μM; high ADP: 10 μM; low collagen: 0.5–4 μg/mL; high collagen: 10 μg/mL; low TRAP: 1–1.5 μM; high TRAP: 10–14 μM; = 9–12, each). (b) Treatment of animals with the SHP-1 inhibitor sodium stibogluconate (10 μg/mL, 30 min) did not affect ADP-induced (6.5 μM) platelet aggregation ex vivo, neither under basal conditions nor in TNFα-induced inflammation (TNFα 5 ng/mL, 4 h, animals per group). SG: sodium stibogluconate, AU: arbitrary unite.
